Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Sabine Danzinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: sabine.danzi…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medizinische Universität Wien.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Neoadjuvant chemotherapy (NACT) is an established form of therapy for early breast cancer (BC). The aim of our study was to analyze histopathological parameters before and after receiving NACT and to determine the influence of these changes on prognosis of BC patients. MATERIAL AND METHODS: We retrospectively analyzed data of patients with primary early BC, diagnosed between January 2012 and December 2019, and NACT, followed by primary surgery. Patients achieving pathological complete response (pCR) were excluded. For the outcome analysis, disease-free survival (DFS) and overall survival (OS) were defined. RESULTS: A total of 237 tumors were analyzed in the study. The conversion rates of tumor grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67 status, and BC subtype were 34.6 %, 3.4 %, 14.3 %, 4.6 %, 30.0 %, and 28.7 %, respectively. After a median follow-up of 58.03 months, we found an association between consistently negative ER/PR with the worst prognosis (DFS and OS) (ER p < 0.0001 for both; PR p = 0.0003, p = 0.0004, respectively). The conversion from Ki67 ≥14 % to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: sabine.danzinger@meduniwien.ac.at.
- Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: verena.heissspornberger@meduniwien.ac.at.
- Center for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria. Electronic address: hannes.vietzen@meduniwien.ac.at.
- Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: kristina.tendl-schulz@meduniwien.ac.at.
- Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: georg.pfeiler@meduniwien.ac.at.
- Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: christian.singer@meduniwien.ac.at.
Förderung
- Medizinische Universität Wien
Zitieren
APA
Danzinger, S., Spornberger, V. H., Vietzen, H., Tendl-Schulz, K., Pfeiler, G., Singer, C. F., & Seifert, M. (2025). Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100886
Vancouver
Danzinger S, Spornberger VH, Vietzen H, Tendl-Schulz K, Pfeiler G, Singer CF, et al. Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100886
BibTeX
@article{Danzinger2025,
author = {Danzinger, Sabine and Spornberger, Verena Heiss and Vietzen, Hannes and Tendl-Schulz, Kristina and Pfeiler, Georg and Singer, Christian F and Seifert, Michael},
title = {Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100886}
}
EUVIMED